At MavriX Bio, our mission is to bring potentially life-changing therapies to individuals living with AS. We approach our work every day with great urgency and commitment to the individuals and families who suffer from this devastating disorder for which there are no treatment options.

 

What is Expanded Access?

 

Expanded access—also known as compassionate use—is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational therapies outside of a clinical trial, when no comparable or satisfactory alternative therapy options are available. These programs are subject to regulatory oversight and require certain criteria to be met to ensure patient safety and appropriate use of the investigational product.

 

MavriX Bio’s Position on Expanded Access

 

We understand that patients and families facing serious or life-threatening conditions may seek access to investigational therapies outside of clinical trials. At this time, MavriX Bio is not offering an expanded access program for MVX-220.

 

We believe that the most efficient and scientifically rigorous way to assess the potential of MVX-220 is through clinical studies designed to generate the data required for regulatory review and potential future approval.

 

Future Updates

 

MavriX Bio will continue to evaluate our access policies as our development program progresses. If our position on expanded access changes in the future, we will provide updates on this page.